Page last updated: 2024-12-11

oxilorphan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

oxilorphan: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5361090
CHEMBL ID2106993
SCHEMBL ID298450
MeSH IDM0052834

Synonyms (34)

Synonym
morphinan-3,14-diol, 17-(cyclopropylmethyl)-
oxilorfano [inn-spanish]
levo-bc 2605
oxilorphan [usan:inn]
bristol laboratories bc 2605
oxilorphane [inn-french]
einecs 255-749-8
(-)-3,14-dihydroxy-n-(cyclobutylmethyl)morphinan
(-)-17-cyclopropylmethylmorphinan-3,4-diol
(-)-17-(cyclopropylmethyl)morphinan-3,14-diol
(l)-bc-2605
l-n-cyclopropylmethyl-3,14-dihydroxymorphinan
oxilorphanum [inn-latin]
D05299
oxilorphan (usan/inn)
42281-59-4
levo-bc-2605
oxilorphan
CHEMBL2106993
oxilorfano
oxilorphanum
9y9j2j74to ,
oxilorphane
unii-9y9j2j74to
SCHEMBL298450
oxilorphan [inn]
oxilorphan [usan]
STBZIDOIKQNFCQ-HSALFYBXSA-N
n-cyclopropylmethyl-3,14-dihydroxymorphinan
DTXSID001009897
(4bs,8as,9r)-11-(cyclopropylmethyl)-5,6,7,8,9,10-hexahydro-8ah-9,4b-(epiminoethano)phenanthrene-3,8a-diol
Q7115662
(1s,9r,10s)-17-(cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol
AKOS040747241

Research Excerpts

Effects

ExcerptReferenceRelevance
"Oxilorphan has partial agonist properties similar to dl-cyclazocine."( Partial agonist properties and toxicity of oral oxilorphan.
Sellers, EM; Thakur, R, 1976
)
1.23

Treatment

ExcerptReferenceRelevance
"Treatment with oxilorphan did not interfere with the response to ADH infusion in water-loaded subjects."( Role of endogenous opioids in neurohypophysial function of man.
Miller, M, 1980
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1148435Narcotic antagonist activity in sc dosed mouse assessed as reversal of oxymorphone-induced narcosis1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Analgesics and narcotic antagonists in the benzomorphan and 8-oxamorphinan series. 5.
AID1135281Analgesic activity in sc dosed mouse assessed as reduction in phenylquinone-induced writhing administered 15 mins prior to phenylquinone-challenge measured up to 10 mins1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
5-allyl-9-oxobenzomorphans. 3. Potent narcotic antagonists and analgesics-antagonists in the series of substituted 2',9beta-dihydroxy-6,7-benzomorphans.
AID1148436Antagonist activity in rat assessed as morphine-induced analgesia by hot plate tail flick test1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Analgesics and narcotic antagonists in the benzomorphan and 8-oxamorphinan series. 5.
AID1135289Narcotic antagonist activity in sc dosed mouse assessed as inhibition of oxymorphone-induced straub tail response administered 10 mins post oxymorphone-challenge1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
5-allyl-9-oxobenzomorphans. 3. Potent narcotic antagonists and analgesics-antagonists in the series of substituted 2',9beta-dihydroxy-6,7-benzomorphans.
AID1135279Narcotic antagonist activity in sc dosed rat assessed as reversal of oxymorphone-induced loss of righting reflex1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
5-allyl-9-oxobenzomorphans. 3. Potent narcotic antagonists and analgesics-antagonists in the series of substituted 2',9beta-dihydroxy-6,7-benzomorphans.
AID1148432Analgesic activity in sc dosed mouse assessed as phenylquinone-induced writhing measured for 10 mins1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Analgesics and narcotic antagonists in the benzomorphan and 8-oxamorphinan series. 5.
AID1148434Analgesic activity in sc dosed rat assessed as phenylquinone-induced writhing measured for 10 mins1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Analgesics and narcotic antagonists in the benzomorphan and 8-oxamorphinan series. 5.
AID1148433Narcotic antagonist activity in sc dosed mouse assessed as reversal of oxymorphone-induced straub tail response administered 10 mins before oxymorphone challenge1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Analgesics and narcotic antagonists in the benzomorphan and 8-oxamorphinan series. 5.
AID1135278Narcotic antagonist activity in sc dosed rat assessed as reversal of morphine-induced analgesia by tail-flick test1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
5-allyl-9-oxobenzomorphans. 3. Potent narcotic antagonists and analgesics-antagonists in the series of substituted 2',9beta-dihydroxy-6,7-benzomorphans.
AID1135280Analgesic activity in sc dosed rat assessed as reduction in phenylquinone-induced writhing administered 15 mins prior to phenylquinone-challenge measured up to 10 mins1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
5-allyl-9-oxobenzomorphans. 3. Potent narcotic antagonists and analgesics-antagonists in the series of substituted 2',9beta-dihydroxy-6,7-benzomorphans.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-199011 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.52 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (9.09%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]